POC Clinical Program of a New Anti-Tumor Drug Candidate MBC-11 Targeting Metastatic Bone Disease Read more: Maxwell Biotech Venture Fund Invests in POC Clinical Program of a New Anti-Tumor Drug Candi
In early September the investment committee of Maxwell Biotech Venture Fund (âMBVFâ), founded with the participation of the Russian Governmentâs RVC, approved the binding terms and the amount of an investment in a newly established private Russian biotech company, Osteros Biomedica, Ltd, formed for the development and commercialization of drugs for the treatment of cancer-induced bone disease.
The World Summit on Innovation & Entrepreneurship, Boston, September 26-28, 2012. KCA was one of 40 special invited guests.
48% more likely to develop kidney cancer due to poor oral health
The center is launching its Moon Shots ProgramÂÂ as a way to rally up researchers, and put an end to cancer.
48% greater risk of kidney cancer seen among those with gum disease.
The Supreme Court is hearing a case which could well determine whether patients grappling with deadly diseases can have access to affordable generic medicines.
Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer
This phase II trial is studying how well sunitinib works as first-line therapy in treating patients with locally advanced or metastatic papillary renal cell (kidney) cancer.
"We invite kidney cancer advocates from around the world to join us for this inaugural event..."
âWeâre pleased to announce the formation of an international collaboration of cancer patient organizations aimed at speeding innovative treatments from the bench to the bedside,â says Bill Bro, CEO of the Kidney Cancer Association (KCA), the worldâs largest charity dedicated to the eradication of death and suffering from renal cancers.
Inconsistent epidemiological findings, debate over interpretation, and extrapolation of findings from animal studies to humans have produced uncertainty surrounding the carcinogenicity of trichloroethylene (TCE) exposure in occupational settings.